---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021239"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:12:03.739543+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma Q1 net loss $27.8M; focuses Alzheimer's trial on 40 mg dose

## Summary
- Net loss $27.8M ($0.73/share) vs $21.0M ($0.56) in Q1 2022; cash $219.9M.
- Phase 2/3 LIFT-AD trial to focus on 40 mg fosgonimeton; 70 mg arm discontinued.
- Open-label extension extended to up to 30 months; >85% enrollment from prior trials.
- ATH-1105 preclinical data in ALS shows prolonged survival and improved motor function; IND-enabling work for 2024 first-in-human.
- End of Phase 2 meeting with FDA scheduled for summer 2023; timeline update expected.

## SEC filing metadata
- accession: 0000950170-23-021239
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017023021239/0000950170-23-021239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017023021239/atha-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021239
- JSON: https://secwatch.observer/filing/0000950170-23-021239.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021239.txt

## Key facts
- Earnings Releases
  LeonaBio, Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 11, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1620463/000095017023021239/0000950170-23-021239-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.